New Combination Therapy Eliminates Pancreatic Tumours in Mice, Raising Fresh Hope

ଖେଳ

ମୁମ୍ବାଇ ଇଣ୍ଡିଆନ୍ସର ଦୁର୍ଦ୍ଦଶା, ପରାଜୟ ପରେ ହାର୍ଦ୍ଦିକଙ୍କ “No Idea”...

April 18, 2026

ବୁମ୍ରା ଏବେ ଖରାପ ସମୟ ଦେଇ ଯାଉଛନ୍ତି, କିନ୍ତୁ ଥରେ...

April 17, 2026

ଆଇପିଏଲ୍ ୨୦୨୬ରେ ଏପ୍ରିଲ୍ ୨୩ରେ ଫେରିପାରନ୍ତି ଏମ୍‌ଏସ୍‌ ଧୋନି; ମୁମ୍ବାଇ...

April 16, 2026

ଆଇପିଏଲ୍ ୨୦୨୬: ଲକ୍ଷ୍ନୌକୁ ୫ ଉଇକେଟ୍‌ରେ ହରାଇ ଟେବୁଲ୍ ଟପ୍‌ରେ...

April 16, 2026

ବ୍ୟବସାୟ

ଡିଜିଟାଲ ଭାରତରେ ସେକେଣ୍ଡରେ ପେମେଣ୍ଟ, କିନ୍ତୁ ଠକେଇ ମଧ୍ୟ ତେଜିତ

April 18, 2026

କେନ୍ଦ୍ର ସରକାରୀ କର୍ମଚାରୀ ଓ ପେନ୍ସନର୍ମାନଙ୍କ ପାଇଁ 2% ଡିଏ...

April 18, 2026

ସୁପ୍ରିମ କୋର୍ଟ ସନ୍ଦେସରା ଠକେଇ ମାମଲା ବନ୍ଦ କଲା, ₹9,800...

April 18, 2026

କାଗଜରେ ନିୟମିତ, ପ୍ରୟୋଗରେ ଦୁର୍ବଳ: କିପରି ଶ୍ରମ ଆଇନକୁ ନିରବରେ...

April 18, 2026

New Combination Therapy Eliminates Pancreatic Tumours in Mice, Raising Fresh Hope

Scientists in Spain have developed a novel combination therapy that completely eliminated pancreatic tumours in mice. While still in early stages, the breakthrough adds to growing optimism around new immunotherapy and vaccine-based treatments for one of the deadliest cancers.

Published by Somesh | January 30, 2026

Pancreatic cancer remains one of the most lethal malignancies, with nearly 90 percent of patients dying within five years of diagnosis due to late detection and limited treatment options. However, new research from Spain is offering cautious optimism.

Scientists at the Spanish National Cancer Research Centre (CNIO) have designed an experimental combination therapy that successfully eliminated pancreatic tumours in mouse models without significant side effects. The study, published in the journalProceedings of the National Academy of Sciences (PNAS), combines multiple immunotherapy approaches, including a cancer vaccine with immune-boosting adjuvants and checkpoint inhibitors.

The therapy targets the cancer’s natural resistance mechanisms by blocking the KRAS oncogene at three different points in its signalling pathway. KRAS mutations are present in nearly 90 percent of pancreatic cancer cases and are a major reason why existing treatments often fail. By attacking the pathway at multiple levels, researchers were able to prevent tumours from developing resistance and eliminate them permanently in mice.

The findings come shortly after encouraging results from an early human trial of a personalised mRNA pancreatic cancer vaccine in the United States, further strengthening interest in combination and vaccine-driven therapies. While the Spanish research is still far from human clinical trials, experts believe it represents an important step toward improving survival outcomes for pancreatic ductal adenocarcinoma, the most common form of the disease.